A study comparing two different combinations for giving anaesthesia in short surgeries

Comparison of Dexmedetomidine and ketamine versus fentanyl and propofol for short surgical procedures under general anaesthesia - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/093390

Enrollment

Registered

2025-08-21

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Dexmedetomidine and ketamine: for short surgical procedures under general anaesthesia Intervention2: fentanyl and propofol: for short surgical procedures under general anaesthesia Contr

Eligibility

Inclusion criteria

Inclusion criteria: Age between 18 - 60 years (Both Males and Females) ASA Grade 1 and 2 Undergoing Short Surgical Procedures (less than 60 mins)

Exclusion criteria

Exclusion criteria: Patient refusal ASA grade 3 and 4 Posted for Emergency Surgeries Allergy to Propofol and dexmedetomidine CVS Disorders Liver or Renal Dysfunction

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of dexmedetomidine and ketamine versus fentanyl and propofol for intraoperative analgesia and anaesthesia and to assess hemodynamic stabilityTimepoint: From 15 mins to 1 hour Intraoperatively	—

Secondary

Measure	Time frame
To compare postoperative recovery profiles including emergence time,sedation,pain score & incidence of postoperative nausea & vomiting between dexmedetomidine & ketamine & fentanyl & propofol groupsTimepoint: From 15 mins to 6 hour postoperatively in PAICU	—

Countries

India

Contacts

Public ContactDr M Mohamed Asiq

Vinayaka Missions Kirupananda Variyar Medical College and Hospitals Chinnaseeragapadi Salem

naveenasen@gmail.com9486198407

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026